Confo Therapeutics Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
82
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$1.17M
- Investors
-
19
Confo Therapeutics General Information
Description
Developer of a drug discovery platform intended to identify medicines targeting G protein-coupled receptors. The company utilizes proprietary single-domain antibodies to stabilize functional receptor conformations, enabling the discovery of small molecules and antibodies for metabolic, endocrine, and chronic pain conditions, enabling pharmaceutical partners to access previously inaccessible therapeutic targets.
Contact Information
Website
www.confotherapeutics.comCorporate Office
- Technologiepark-Zwijnaarde 30
- Zwijnaarde
- 9052 Ghent
- Belgium
Corporate Office
- Technologiepark-Zwijnaarde 30
- Zwijnaarde
- 9052 Ghent
- Belgium
Confo Therapeutics Timeline
Confo Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Grant | 08-Oct-2025 | $1.17M | Completed | Clinical Trials - Phase 1 | ||
| 11. Later Stage VC (Series B) | 26-Jul-2024 | Completed | Clinical Trials - Phase 1 | |||
| 10. Grant | 28-Mar-2024 | Completed | Clinical Trials - Phase 1 | |||
| 9. Grant | 28-Jun-2022 | Completed | Clinical Trials - Phase 1 | |||
| 8. Grant | 30-Mar-2021 | Completed | Clinical Trials - Phase 1 | |||
| 7. Grant | 20-Jun-2019 | Completed | Clinical Trials - Phase 1 | |||
| 6. Early Stage VC (Series A) | 01-May-2019 | Completed | Clinical Trials - Phase 1 | |||
| 5. Grant | 20-Feb-2018 | Completed | Clinical Trials - Phase 1 | |||
| 4. Grant | 01-Feb-2017 | $2.74M | $7.28M | Completed | Clinical Trials - Phase 1 | |
| 3. Early Stage VC | 01-Feb-2016 | $7.28M | $7.28M | Completed | Clinical Trials - Phase 1 |
Confo Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Class C | ||||||||
| Class C | ||||||||
| Class B2 | 4,917,475 | $6.5 | $6.5 | 1x | $6.5 | 38.45% | ||
| Class B | 800,000 | $4.33 | $4.33 | 1x | $4.33 | 6.26% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Confo Therapeutics Comparisons
Industry
Financing
Details
Confo Therapeutics Competitors (93)
One of Confo Therapeutics’s 93 competitors is Marengo Therapeutics, a Venture Capital-Backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Marengo Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Alzheon | Venture Capital-Backed | Framingham, MA | ||||
| Lisata Therapeutics | Corporation | Basking Ridge, NJ | ||||
| Biomunex Pharmaceuticals | Venture Capital-Backed | Paris, France |
Confo Therapeutics Patents
Confo Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4605077-A1 | Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders | Pending | 18-Oct-2022 | ||
| US-20260103529-A1 | Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders | Pending | 18-Oct-2022 | ||
| WO-2024083843-A1 | Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders | Inactive | 18-Oct-2022 | ||
| AU-2022318349-A1 | Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling | Active | 30-Jul-2021 | ||
| AU-2022318349-B2 | Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling | Active | 30-Jul-2021 | C07D403/14 |
Confo Therapeutics Signals
Confo Therapeutics Investors (19)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Ackermans & van Haaren | Growth/Expansion | Minority | ||
| Driehaus Capital Management | Corporation | Minority | ||
| Quest For Growth | Asset Manager | Minority | ||
| BioGeneration Ventures | Venture Capital | Minority | ||
| Fund+ | Venture Capital | Minority |
Confo Therapeutics FAQs
-
When was Confo Therapeutics founded?
Confo Therapeutics was founded in 2015.
-
Where is Confo Therapeutics headquartered?
Confo Therapeutics is headquartered in Ghent, Belgium.
-
What is the size of Confo Therapeutics?
Confo Therapeutics has 82 total employees.
-
What industry is Confo Therapeutics in?
Confo Therapeutics’s primary industry is Drug Discovery.
-
Is Confo Therapeutics a private or public company?
Confo Therapeutics is a Private company.
-
What is Confo Therapeutics’s current revenue?
The current revenue for Confo Therapeutics is .
-
How much funding has Confo Therapeutics raised over time?
Confo Therapeutics has raised $105M.
-
Who are Confo Therapeutics’s investors?
Ackermans & van Haaren, Driehaus Capital Management, Quest For Growth, BioGeneration Ventures, and Fund+ are 5 of 19 investors who have invested in Confo Therapeutics.
-
Who are Confo Therapeutics’s competitors?
Marengo Therapeutics, CytomX Therapeutics, Alzheon, Lisata Therapeutics, and Biomunex Pharmaceuticals are some of the 93 competitors of Confo Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process